Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells

Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote an immunosuppressive tumor microenvironment. Previous studies demonstrated that focal adhesion kinase inhibitors (FAKi) in clinical development inhibit the infiltration of suppressive myeloid cells and T regulatory (T regs) cells, and subsequently enhance effector T cell infiltration. FAK inhibitors in clinical development have not been investigated in combination with RT in preclinical murine models or clinical studies. Thus, we investigated the impact of FAK inhibition on RT, its potential as an RT sensitizer and immunomodulator in a murine model of PDAC. Methods: We used a syngeneic orthotopic murine model to study the effect of FAKi on hypofractionated RT. Results: In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT. Antitumor activity of the combination of FAKi and RT is T cell dependent. FAKi in combination with RT enhanced CD8+ T cell infiltration significantly in comparison to the radiation or FAKi treatment alone (P < 0.05). FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone (P < 0.01). Conclusions: These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy.

[1]  Jordan M. Blum,et al.  Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer , 2020, Journal for ImmunoTherapy of Cancer.

[2]  I. Waizenegger,et al.  T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity , 2020, eLife.

[3]  Cierra S. Hong,et al.  Neutrophils promote tumor resistance to radiation therapy , 2019, Proceedings of the National Academy of Sciences.

[4]  A. Osipov,et al.  Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape , 2019, Journal of Immunotherapy for Cancer.

[5]  C. Belka,et al.  Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches , 2019, Radiation oncology.

[6]  R. Boidot,et al.  Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination , 2019, Journal of Immunotherapy for Cancer.

[7]  S. Ostrand-Rosenberg,et al.  Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy , 2019, Front. Oncol..

[8]  H. Hirte,et al.  Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies , 2019, Targeted Oncology.

[9]  I. Waizenegger,et al.  The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer , 2018, Oncogenesis.

[10]  M. Makary,et al.  Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? , 2018, Annals of surgery.

[11]  J. Gong,et al.  Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination , 2018, Journal of Immunotherapy for Cancer.

[12]  L. Ratner,et al.  Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. , 2018 .

[13]  I. Waizenegger,et al.  Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype , 2018, Oncogenesis.

[14]  T. Crocenzi,et al.  A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma , 2016, Journal of Immunotherapy for Cancer.

[15]  Zhi-rui Zhou,et al.  HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo , 2016, Oncotarget.

[16]  C. N. Coleman,et al.  Radiotherapy: Changing the Game in Immunotherapy. , 2016, Trends in cancer.

[17]  J. Morales,et al.  Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer , 2016, Clinical Cancer Research.

[18]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[19]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[20]  P. Tamayo,et al.  A genetic basis for the variation in the vulnerability of cancer to DNA damage , 2016, Nature Communications.

[21]  Jing Wang,et al.  Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer , 2016, Clinical Cancer Research.

[22]  Adam Byron,et al.  Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity , 2015, Cell.

[23]  C. Iacobuzio-Donahue,et al.  Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer , 2015, Science Signaling.

[24]  P. Tran,et al.  The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma , 2015, American journal of clinical oncology.

[25]  C. Willett,et al.  Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. , 2015, Journal of gastrointestinal oncology.

[26]  Albert C. Koong,et al.  Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.

[27]  R. Hruban,et al.  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.

[28]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[29]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[30]  R. Abrams,et al.  Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial , 2011, Annals of Surgical Oncology.

[31]  W. Regine,et al.  Analysis of local control in patients receiving IMRT for resected pancreatic cancers. , 2010, International journal of radiation oncology, biology, physics.

[32]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[33]  T. Lawrence,et al.  Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. , 2008, Translational oncology.

[34]  C. Pilarsky,et al.  Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1 , 2007, Oncogene.

[35]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[36]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[37]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[38]  S. Formenti,et al.  Myeloid-derived cells in tumors: effects of radiation. , 2015, Seminars in radiation oncology.

[39]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.